临床特征对新诊断患者抗药剂量的影响
Hire Hersi1,2, Jukka Peltola2,3, Jani Raitanen4
1Department of Neurology, Vaasa Central Hospital, Vaasa, Finland.
Frontiers in neurology
|August 23, 2023
概括
抗发作药物 (ASM) 的剂量因患者的年龄,性别和发作类型而异. 根据这些临床因素量身定制初始ASM剂量可以优化治疗控制.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 新发作的需要有效的抗发作药物 (ASM) 管理.
- 优化ASM剂量对于实现无发作和尽量减少副作用至关重要.
- 了解影响ASM剂量的因素可以个性化治疗策略.
研究的目的:
- 研究临床特征对ASM剂量对新发的成年患者的影响.
- 为了比较无和无患者组之间的ASM剂量.
- 为了确定与特定ASM剂量相关的患者特征.
主要方法:
- 对459名经过验证的新发诊断的患者进行了回顾性分析.
- 对常规处方的ASM剂量的评估:牛炭卜素 (OXC),烯酸 (VPA),碳卜素 (CBZ) 和拉莫特里金 (LTG).
- 统计分析以确定ASM剂量与患者特征 (如年龄,性别和发作类型) 之间的关联.
主要成果:
- 在老年患者 (>60岁) 和没有的患者中,氧化碳bazepine (OXC) 的剂量较低.
- 酸 (VPA) 剂量在男性和未实现自由的患者中较高.
- 卡巴马泽平 (CBZ) 的剂量根据发作类型 (FAS与FBTCS) 不同.
结论:
- 在年龄组之间观察到OXC剂量的显著差异.
- 根据性别和控制状态,VPA剂量显示出差异.
- CBZ剂量受特定发作类型的影响,支持个性化剂量策略.
更多相关视频
相关概念视频
Antiepileptic Drugs: Sodium Channel Blockers
664
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
664
Antiepileptic Drugs: Potassium Channel Activators
211
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
211
Antiepileptic Drugs: Calcium Channel Blockers
453
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
453
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
344
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
344
Arteries of the Lower Limbs
213
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
213
Antiepileptic Drugs: GABAergic Pathway Potentiators
460
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
460


